The global biosimilar market is expected to grow significantly from USD 3,748 million in 2017 to USD 34,865 million in 2024, at a CAGR of 32.6% from 2018 to 2024.
The biosimilars company Formycon is appointing Thomas Siklosi, a former board member of Rentschler Biopharma SE, to its Advisory Board. Siklosi is a renowned biotech manager and expert in the development and production of biologics and biosimilars with 34 years of professional experience in this field.
Celltrion, Inc. is set to launch global Phase 3 clinical trial for its bevacizumab biosimilar ‘CT-P16’ for the treatment of cancer. Celltrion successfully completed Phase 1 clinical study on the safety and pharmacokinetic assessment of CT-P16 in June 2018.
The Biosimilars Forum is encouraged by the announcement from the Centers for Medicare and Medicaid Services (CMS) and their continued efforts to increase access to biosimilars and drive competition to improve affordability for patients.
JHL Biotech has announced it received a positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the EU approval pathway for its proposed trastuzumab biosimilar, JHL1188, to treat breast cancer.
JHL Biotech has announced it received a positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the EU approval pathway for its proposed bevacizumab biosimilar, JHL1149 to treat patients with non-small cell lung cancer (NSCLC).
Despite drugmaker promises to limit price increases, their ongoing efforts to game the system by delaying generic competition, blocking safe and effective biosimilars and refusing to eliminate list price increases are the main reasons medication remains unaffordable for many people.
Celltrion applied for the clinical trials for its adalimumab biosimilar ‘CT-P17’, as a rheumatoid arthritis therapeutic agent, to the MHRA (Medicines and Healthcare Products Regulatory Agency) in the UK.
Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, recently announced that the first patient was dosed in a Phase I trial of SCB-808, a proposed biosimilar of Enbrel (etanercept) being developed in the prefilled syringe formulation for the treatment of rheumatoid arthritis and other autoimmune diseases.
|
|
|
|
|
|
|
|
|